Teleconferência de Resultados do 3T de 2026 da Mobia Medical (MOBI): Receita Sobe 73%, Guidance Elevado
A receita da Mobia Medical (MOBI) no terceiro trimestre de 2026 subiu 73%, para US$ 15,6 milhões, a margem bruta atingiu 83,2% e o guidance de receita para o ano todo foi elevado.
Mobia Medical, Inc. is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The Company’s Vivistim Paired Vagus Nerve Stimulation (Paired VNS) System is the clinically validated, FDA-approved solution for chronic ischemic stroke survivors with moderate to severe upper extremity impairments. The Vivistim System includes an implantable device that stimulates the vagus nerve only when intentionally activated, triggering the release of neuromodulators, including acetylcholine, norepinephrine, and serotonin. Its neuromodulators create a heightened state of plasticity in the brain, such that neural networks can more readily adapt and reform in response to stimuli. The implantable components of the Vivistim System-namely, the implantable pulse generator (IPG) and lead-are implanted through a minimally invasive outpatient procedure that takes approximately 60 minutes.